A sore injection site is the most commonly reported local adverse reaction in clinical trials of injectable testosterone. What we see readers get wrong most often is which product the boxed warning actually belongs to. The physical depot itself drives most post-injection discomfort. Injected vegetable oils spread along muscle fibers and take weeks to clear from local tissue.
The Verdict
What Clinical Trials Actually Recorded
Clinical trial records show that localized injection site reactions occur in 4% to 13% of patients receiving injectable testosterone. Across the clinical development programme for XYOSTED, 36 of 283 patients reported injection site reactions, representing 12.7% of participants treated for up to one year. The manufacturer lists local site reactions as the product's most common adverse reaction.
The specific symptoms recorded in those studies followed a consistent pattern. In the 1-year study of 150 men, the label records bruising in 6.7%, hemorrhage in 3.3%, and erythema in 2.7%. The separate 6-month study reported bruising in 3.8% and hemorrhage in 6.0%.
Trials of intramuscular formulations document comparable local events. In the 84-week clinical trial of AVEED involving 153 patients, the label reports injection site pain in 4.6% and erythema in 1.3%. Older intramuscular products report symptoms without frequency data. The Depo-Testosterone label lists local inflammation and pain under adverse reactions without a percentage. The generic testosterone enanthate label similarly notes pain and inflammation without an incidence rate.
| Product and Ester | Route and Carrier | Reported Local Reaction Rates | Documented Symptoms |
|---|---|---|---|
| XYOSTED (testosterone enanthate) | Subcutaneous autoinjector; sesame oil | 12.7% overall across 283 patients in 2 studies | Bruising (3.8% to 6.7%), hemorrhage (3.3% to 6.0%), erythema (2.7%), induration |
| AVEED (testosterone undecanoate) | Intramuscular; refined castor oil and benzyl benzoate | 4.6% pain in 153 patients followed for 84 weeks | Injection site pain, erythema (1.3%) |
| Depo-Testosterone (testosterone cypionate) | Intramuscular; cottonseed oil and benzyl benzoate | Unspecified incidence in prescribing information | Local inflammation and pain at intramuscular site |
| Generic testosterone enanthate USP | Intramuscular; sesame oil and chlorobutanol | Unspecified incidence in prescribing information | Local inflammation and pain at injection site |
Carrier Oil Persistence and Depot Dynamics
The physical persistence of the carrier oil vehicle inside tissue explains why injection sites remain sore for multiple days. A pharmaceutics review by Larsen and Larsen in The AAPS Journal describes what happens when lipophilic solutions enter muscle. The oil vehicle spreads significantly along muscle fibrils upon injection, creating a large interfacial contact area between the oil depot and surrounding tissue fluids.
Drug release depends on the active hormone partitioning between the oil vehicle and adjacent interstitial fluid. The oil itself does not dissolve rapidly. In animal models, vehicle clearance half-lives reached approximately 23 days for sesame oil, 20 days for castor oil, and 14 days for fractionated coconut oil. A physical depot remains present in tissue for several weeks after each injection.
Preservatives and co-solvents modify the chemical profile of that depot. Depo-Testosterone contains benzyl benzoate and benzyl alcohol alongside cottonseed oil. The 200 mg/mL strength contains 0.2 mL of benzyl benzoate per mL, whereas the 100 mg/mL strength contains 0.1 mL. Generic testosterone enanthate pairs sesame oil with chlorobutanol. Low temperatures can also alter the fluid state. The Depo-Testosterone label notes that testosterone cypionate can crystallize out of solution if stored below recommended temperatures, requiring warming and shaking to redissolve the ester.
The Counterintuitive Viscosity and Volume Findings
Higher fluid viscosity produced less injection pain in controlled trials than thinner solutions. A randomised crossover Phase I study led by Berteau and published in Medical Devices: Evidence and Research evaluated 24 healthy adults receiving six subcutaneous abdominal injections. The researchers tested three viscosities (1, 8 to 10, and 15 to 20 centipoise), two injection volumes (2 mL and 3 mL), and two flow rates (0.02 and 0.30 mL per second).
Fluid viscosity significantly altered perceived pain scores. Injections of high-viscosity solutions produced a mean visual analog scale pain score of 12.6 mm. Medium viscosity produced 16.6 mm. Low viscosity produced 22.1 mm. The difference between high and low viscosity reached statistical significance at p=0.0002. Neither injection volume nor injection speed showed any significant effect on pain. Comparing 2 mL against 3 mL yielded p=0.89, while comparing slow against fast injection rates yielded p=0.79.
A clear boundary limits those findings. The Berteau trial tested aqueous placebo solutions with viscosities capped at 20 centipoise. Injectable vegetable oils such as sesame, cottonseed, and castor oil exhibit substantially higher viscosities. The trial demonstrates that fluid thickness does not automatically increase injection discomfort in subcutaneous tissue, but it did not measure commercial testosterone preparations directly.
Intramuscular Versus Subcutaneous Injection Reactions
Subcutaneous and intramuscular delivery routes produce comparable circulating hormone concentrations while presenting distinct local tolerability profiles. A retrospective study of 234 hypogonadal men by Choi and colleagues in The Journal of Urology evaluated weekly regimens. Intramuscular testosterone cypionate increased mean total testosterone from 313.6 to 536.4 ng/dL. Subcutaneous testosterone enanthate delivered by autoinjector increased levels from 246.6 to 552.8 ng/dL. Delivery route was not independently associated with final testosterone concentrations.
The two groups showed differences in secondary biomarkers. Men in the subcutaneous group experienced lower post-therapy estradiol and lower haematocrit readings. That trial carried an important confound. The investigators compared intramuscular cypionate against subcutaneous enanthate, meaning ester dynamics and injection route varied at the same time. Our analysis of TRT delivery routes details how those kinetic profiles compare across formulations.
Tissue physiology explains the differences in local reactions. A review by Figueiredo, Gagliano-Jucá, and Basaria in The Journal of Clinical Endocrinology & Metabolism notes that subcutaneous adipose tissue is less vascularised than skeletal muscle. Lymphatic drainage in subcutaneous fat depends on intrinsic lymphatic pumping. Intramuscular tissue benefits from additional extrinsic pumping during physical movement. Clinical trials of subcutaneous enanthate documented frequent mild events including bruising, induration, hematoma, and transient itching, but recorded no serious tissue damage.
Prescribing Label Route Instructions and Omissions
United States prescribing labels designate specific anatomical routes for each approved testosterone preparation. The XYOSTED label specifies administration for subcutaneous injection in the abdominal region only, directing clinicians to avoid intramuscular or intravascular delivery. The Depo-Testosterone label directs that intramuscular injections should be given deep in the gluteal muscle and states the product is not for intravenous use.
Generic testosterone enanthate carries the explicit heading that it is for intramuscular use only. The AVEED label instructs clinicians to inject deeply into the gluteal muscle while taking care to avoid intravascular injection, the superior gluteal arteries, and the sciatic nerve.
Injection duration instructions appear on only one product. The AVEED label directs administrators to inject the 3 mL volume slowly over 60 to 90 seconds at a constant rate. The manufacturer frames that duration as a precaution against inadvertent intravascular administration rather than a method to reduce injection pain. Across all four approved injectable labels, none contains text instructing clinicians or patients on injection site rotation.
Pulmonary Oil Microembolism and Safety Warnings
Testosterone undecanoate is the only injectable testosterone formulation in the United States that carries a boxed warning for pulmonary oil microembolism and anaphylaxis. The AVEED boxed warning describes serious reactions involving an urge to cough, dyspnea, throat tightening, chest pain, dizziness, and syncope occurring during or immediately after administration. These events can occur after any injection during therapy, including the first dose. The product requires a 30-minute observation period in a healthcare setting under a Risk Evaluation and Mitigation Strategy program.
A postmarketing safety analysis published by Pastuszak, Hu, and Freid in Sexual Medicine examined 90,092 distributed doses of intramuscular testosterone undecanoate over 4.3 years. The rate of spontaneously reported pulmonary oil microembolism was under 0.1% per injection annually. Among cases with documented timing, 94.7% began within 30 minutes of injection. Most cases resolved within 30 minutes to 3 hours, and 95.5% achieved complete resolution.
Coughing episodes also appear in reports for other esters. The generic testosterone enanthate label reports rare post-marketing cases of coughing fits and respiratory distress immediately following injection. Clinical practice guidelines from The Endocrine Society attribute post-injection cough to pulmonary oil microembolism while noting its mechanism remains unconfirmed. Depo-Testosterone contains no label warning regarding cough or pulmonary microembolism.
Clinical Signs of Infection Versus Benign Reactions
Clinical practice guidelines distinguish expected tissue reactions from bacterial soft tissue infections using objective inflammatory criteria. The 2014 skin and soft tissue infection guideline from the Infectious Diseases Society of America defines a cutaneous abscess as a collection of pus within the dermis and deeper skin tissues. These lesions present as painful, fluctuant red nodules surmounted by a pustule and encircled by erythematous swelling.
The guideline identifies erythema and induration extending more than 5 cm from the injection point as a marker of more extensive soft tissue infection. It grades severe infection by the presence of systemic inflammatory response syndrome signs. Those systemic markers include an oral temperature above 38°C or below 36°C, a heart rate above 90 beats per minute, a respiratory rate above 24 breaths per minute, or an abnormal white blood cell count.
Infection confirmed in clinical trials remains rare. In a cohort of 63 men receiving subcutaneous therapy reviewed in The Journal of Clinical Endocrinology & Metabolism, investigators observed ten local reactions across nine patients. These consisted of four transient painless nodules, two cases of urticaria, two instances of localized inflammation, and a single self-limited episode of cellulitis. Guidelines from the Centers for Disease Control and Prevention stress single-use sterile syringes and aseptic technique to prevent bacterial entry during parenteral drug administration.
| Feature | Expected Local Tissue Reaction | IDSA-Defined Soft Tissue Infection Criteria |
|---|---|---|
| Onset Timing | Develops within hours of injection; peaks over 24 to 48 hours | Often emerges or progressively worsens days after administration |
| Tissue Consistency | Firm muscular soreness or small subcutaneous induration | Fluctuant nodule, collection of pus, or bullae formation |
| Erythema Margin | Localized redness confined near the needle puncture site | Erythema and induration extending more than 5 cm from the site |
| Systemic Signs | Absent; normal temperature, pulse, and respiration | Fever (>38°C), tachycardia (>90 bpm), or tachypnea (>24 bpm) |
Compounding Standards and Product Quality
Compounded testosterone formulations are prepared under different regulatory frameworks than commercially approved brand or generic products. The Food and Drug Administration states that compounded drugs are not FDA-approved, meaning the agency does not verify their safety, effectiveness, or manufacturing quality before marketing. Poor compounding practices can cause product contamination or potency variations.
Regulatory standards differ across compounding facilities. State-licensed pharmacies operating under Section 503A are exempt from current good manufacturing practice regulations. Outsourcing facilities operating under Section 503B must comply with current good manufacturing practice requirements. Sterile compounding across both settings is governed by standards such as General Chapter 797 from the United States Pharmacopeia, which establishes practices to prevent microbial contamination and bacterial endotoxins.
Evidence directly comparing local tolerability between compounded and commercial products is limited. No published clinical trial has evaluated injection site reaction rates between compounded testosterone and FDA-approved injectables. Differences in carrier oil selection, solvent concentration, or filtration standards represent potential sources of variability in tissue tolerability. Our review of compounded versus commercial testosterone examines the quality differences between these sources.
Editorial Verdict and Limits of the Evidence
Clinical trial records demonstrate that local injection soreness is an expected consequence of depositing viscous oils into skeletal muscle or adipose tissue. Up to 12.7% of trial participants report local bruising, pain, or induration, driven primarily by oil persistence and tissue displacement rather than product defects. Mild, localized soreness that gradually improves represents the typical clinical course described in drug labeling.
This evidence does not apply to individuals experiencing systemic symptoms. Patients demonstrating signs of infection defined by the Infectious Diseases Society of America, such as fever, tachycardia, or spreading erythema exceeding 5 cm, fall outside the expected profile of benign injection reactions. It also does not apply to men receiving non-injectable therapies such as transdermal gels or oral undecanoate, which avoid intramuscular depots entirely.
What would change our assessment of injection tolerability is direct comparative trial data. A head-to-head trial measuring injection site pain between carrier oils at real vegetable-oil viscosities would replace current inferences with controlled clinical measurements. Similarly, prospective studies comparing local adverse events between compounded formulations and approved commercial products would establish whether compounding practices alter local tissue reactions. Patients reviewing treatment options can explore accredited clinical options through our guide to TRT clinics or evaluate baseline diagnostics with a men's hormone panel.
Frequently Asked Questions
Is it normal for a testosterone injection to hurt the next day?
Yes, localized soreness on the day following an injection is the most common adverse reaction recorded in clinical trials. In trials of subcutaneous testosterone enanthate, 12.7% of patients reported local injection site reactions such as soreness, bruising, or mild swelling. The discomfort results from the oil vehicle itself, which spreads along muscle fibers or subcutaneous fat and takes several weeks to clear. The Depo-Testosterone and generic testosterone enanthate labels both list injection site pain as documented adverse reactions.
How common are testosterone injection site reactions?
Clinical trials report local reactions in 4% to 13% of patients. In the 1-year study of XYOSTED, 6.7% of men experienced bruising, 3.3% had localized hemorrhage, and 2.7% had erythema. In an 84-week study of intramuscular testosterone undecanoate, 4.6% of patients reported injection site pain. Older brand labels for intramuscular testosterone cypionate and enanthate confirm local pain and inflammation occur, but do not provide exact incidence figures.
Why does testosterone injection cause coughing?
Post-injection coughing is associated with pulmonary oil microembolism, a reaction occurring when microscopic oil droplets enter the venous circulation and travel to the capillary beds of the lungs. The AVEED label carries a boxed warning describing cough urges, shortness of breath, and chest tightness immediately after injection. Generic testosterone enanthate labeling also notes rare post-marketing reports of coughing fits. The Endocrine Society clinical guidelines note that post-injection cough is attributed to pulmonary oil microembolism, though its exact mechanism remains unconfirmed.
Does subcutaneous testosterone hurt less than intramuscular?
Comparative trials show both routes produce localized reactions, but with differing physical characteristics. Subcutaneous injections place smaller volumes into abdominal adipose tissue, which is less vascularized and clears fluid primarily through intrinsic lymphatic pumping. Clinical trials of subcutaneous autoinjectors report frequent mild bruising, small nodules, and itching. Intramuscular injections deposit larger volumes into vascular skeletal muscle, leading to deeper muscular soreness. In a trial by Berteau and colleagues, fluid volume between 2 mL and 3 mL did not significantly alter perceived pain scores.
What is POME and which testosterone product carries the warning?
POME stands for pulmonary oil microembolism, a condition where tiny droplets of the injectable oil base reach the lungs. In the United States, AVEED (testosterone undecanoate) is the only formulation carrying a boxed warning for POME and anaphylaxis. In clinical trials, adjudication found 9 POME events in 8 patients, plus 2 anaphylaxis events, among 3,556 patients treated with intramuscular testosterone undecanoate. A postmarketing study of 90,092 distributed doses found POME occurred in fewer than 0.1% of injections annually, with 94.7% of cases beginning within 30 minutes. XYOSTED had its previous boxed warning removed in March 2025, and Depo-Testosterone carries no POME warning.
How do you tell an injection site reaction from an infection?
Clinical guidelines define infections by progressive tissue involvement and systemic inflammation rather than isolated tenderness. The Infectious Diseases Society of America defines soft tissue infection criteria, including erythema and swelling extending more than 5 cm from the injection point, fluctuant fluid collections containing pus, and systemic signs. Systemic signs include a body temperature exceeding 38°C, a heart rate above 90 beats per minute, or elevated respiratory rates. Normal injection reactions remain localized near the puncture site and resolve over several days without systemic fever.
Does the carrier oil change how much the injection hurts?
Carrier oils vary in chemical structure, viscosity, and tissue clearance, but comparative clinical trials measuring pain between specific oils do not exist. FDA-approved injectables use different vehicles: Depo-Testosterone uses cottonseed oil, generic enanthate uses sesame oil, and AVEED uses refined castor oil with benzyl benzoate. Research in The AAPS Journal reports that vehicle clearance half-lives range from 14 days for coconut oil to 23 days for sesame oil. A study in Medical Devices: Evidence and Research found that higher viscosity produced less pain in subcutaneous tissue, though it evaluated aqueous solutions below vegetable-oil viscosity.